Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $3.00 Price Target at Mizuho : vimarsana.com

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective reduced by Mizuho from $4.00 to $3.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. A number of other equities research analysts have also weighed in on the company. The Goldman Sachs Group […]

Related Keywords

United States , Canada , Gina Mazzariello , Joshuab Cohen , Robertw Baird , Qube Research Technologies Ltd , Amylyx Pharmaceuticals , Amylyx Pharmaceuticals Inc , Amylyx Pharmaceuticals Stock Performance , News Ratings For Amylyx Pharmaceuticals Daily , Institutional Trading Of Amylyx Pharmaceuticals , Rafferty Asset Management , Analyst Recommendations For Amylyx Pharmaceuticals , Path Wealth Partners , Goldman Sachs Group , Securities Exchange Commission , Nasdaq , Free Report , Get Free Report , Exchange Commission , Asset Management , Technologies Ltd , Amylyx Pharmaceuticals Daily , Nasdaq Amlx , Amlx , Medical , Lower Price Target , Mizuho ,